150 related articles for article (PubMed ID: 26367749)
21. Acquired epidermodysplasia verruciformis: a comprehensive review and a proposal for treatment.
Zampetti A; Giurdanella F; Manco S; Linder D; Gnarra M; Guerriero G; Feliciani C
Dermatol Surg; 2013 Jul; 39(7):974-80. PubMed ID: 23437916
[TBL] [Abstract][Full Text] [Related]
22. Clinical sequelae associated with squaric acid dibutylester topical sensitization.
Foley S; Blattel SA; Martin AG
Am J Contact Dermat; 1996 Jun; 7(2):104-8. PubMed ID: 8796751
[TBL] [Abstract][Full Text] [Related]
23. Modified immunotherapy for alopecia areata.
Yoshimasu T; Furukawa F
Autoimmun Rev; 2016 Jul; 15(7):664-7. PubMed ID: 26932732
[TBL] [Abstract][Full Text] [Related]
24. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
[TBL] [Abstract][Full Text] [Related]
25. Epidermodysplasia verruciformis and human papilloma virus.
Gewirtzman A; Bartlett B; Tyring S
Curr Opin Infect Dis; 2008 Apr; 21(2):141-6. PubMed ID: 18317036
[TBL] [Abstract][Full Text] [Related]
26. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients.
Avitabile S; Sordi D; Garcovich S; Colonna L; De Luca A; Nasorri F; Mazzanti C; Cavani A
J Dermatol; 2015 Jan; 42(1):98-9. PubMed ID: 25495487
[No Abstract] [Full Text] [Related]
27. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
[TBL] [Abstract][Full Text] [Related]
29. Adjunctive trichloroacetic acid therapy enhances squaric acid response to verruca vulgaris.
Silverberg JI; Silverberg NB
J Drugs Dermatol; 2012 Oct; 11(10):1228-30. PubMed ID: 23134989
[TBL] [Abstract][Full Text] [Related]
30. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod.
Berthelot C; Dickerson MC; Rady P; He Q; Niroomand F; Tyring SK; Pandya AG
J Am Acad Dermatol; 2007 May; 56(5):882-6. PubMed ID: 17368633
[TBL] [Abstract][Full Text] [Related]
31. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis.
Majewski S; Malejczyk J; Jablonska S; Misiewicz J; Rudnicka L; Obalek S; Orth G
J Am Acad Dermatol; 1990 Mar; 22(3):423-7. PubMed ID: 2155952
[TBL] [Abstract][Full Text] [Related]
32. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H
Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of squaric acid dibutyl ester in treatment of recalcitrant warts in children.
Bagherani N
Dermatol Ther; 2015; 28(5):330. PubMed ID: 25817990
[No Abstract] [Full Text] [Related]
34. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
[TBL] [Abstract][Full Text] [Related]
35. Treatment of alopecia areata with topical sensitizers.
Sutherland L; Laschinger M; Syed ZU; Gaspari A
Dermatitis; 2015; 26(1):26-31. PubMed ID: 25581667
[TBL] [Abstract][Full Text] [Related]
36. Epidermodysplasia verruciformis.
Burger B; Itin PH
Curr Probl Dermatol; 2014; 45():123-31. PubMed ID: 24643182
[TBL] [Abstract][Full Text] [Related]
37. Epidermodysplasia verruciformis: association with isolated IgM deficiency and response to treatment with acitretin.
Iraji F; Faghihi G
Clin Exp Dermatol; 2000 Jan; 25(1):41-3. PubMed ID: 10671971
[TBL] [Abstract][Full Text] [Related]
38. Acquired epidermodysplasia verruciformis.
Rogers HD; Macgregor JL; Nord KM; Tyring S; Rady P; Engler DE; Grossman ME
J Am Acad Dermatol; 2009 Feb; 60(2):315-20. PubMed ID: 19150275
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
Ajith C; Gupta S; Kanwar AJ
J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
[TBL] [Abstract][Full Text] [Related]
40. Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report.
Mendes AD; Bittencourt Mde J; Moure ER; D'Macêdo CM; Yamaki IN; Araújo DM
An Bras Dermatol; 2014; 89(1):144-6. PubMed ID: 24626660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
